Goldman Sachs China Equity A (GSAGX)
Nasdaq • Currently unchanged in today's trading session
1 member of Congress has disclosed 1 trade in Goldman Sachs China Equity A (GSAGX) via STOCK Act filings. The most recent disclosure was a sale by James A. Himes on 28 April 2023. Aggregate disclosed activity totals roughly $175K in sales (midpoint estimates from bracketed disclosure amounts).
Goldman Sachs China Equity A is currently trading at $23.94, positioned at 8% of its 52-week range ($23.59 – $28.06).
Want to automatically copy Pelosi trades?
Mirror Nancy Pelosi's portfolio with just one click on eToro.
Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.
Past Performance is not an indication of future results.
Goldman Sachs China Equity A Price History and Technical Analysis
Congressional Trading Activity for GSAGX
| James A. Himes | 28 Apr 2023 | 4 Jun 2024 | Sale | Stock | $100,001 - $250,000 | N/A |
Select transactions to view their annotations on the chart
Similar Stocks
Based on congressional trading patterns
Frequently Asked Questions about GSAGX
- Which members of Congress have traded GSAGX?
- 1 member of Congress has disclosed 1 trade in Goldman Sachs China Equity A (GSAGX) under the STOCK Act: James A. Himes.
- When was GSAGX most recently disclosed by Congress?
- The most recent GSAGX disclosure was a sale by James A. Himes on 28 April 2023.
- What is the total disclosed congressional trading volume for GSAGX?
- Members of Congress have disclosed approximately $175K in GSAGX sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
- How can I track new congressional trades in GSAGX?
- This GSAGX page updates as soon as new STOCK Act disclosures are filed for Goldman Sachs China Equity A. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Track GSAGX in Congress
See when politicians buy or sell this stock